Table 3.

SNP associated with adverse drug reactions from TB patients

Genotypes	Thrombocytopenia (n = 16)		Leukopenia (n = 21)		Hyperbilirubinemia (n = 13)		ATDH (n = 68)		AKI (n = 10)		CKD (n = 12)
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
ABCB1 rs1045642
AG+GG (n = 538)	0.85 (0.24‐3.04)	0.806	0.19 (0.34‐4.11)	0.781	1.09 (0.24‐4.97)	0.915	1.02 (0.52‐2.02)	0.947	1.79 (0.22‐14.25)	0.579	0.58 (0.16‐2.19)	0.428
AA (n = 106)
ABCB1 rs1055302
CT+TT (n = 294)	1.20 (0.44‐3.23)	0.724	1.61 (0.67‐3.88)	0.282	2.73 (0.83‐8.96)	0.085	1.07 (0.64‐1.76)	0.806	1.19 (0.34‐4.16)	0.781	0.85 (0.27‐2.70)	0.780
CC (n = 350)
CYP2D6 rs1135840
GG (n = 344)	1.46 (0.52‐4.06)	0.469	0.64 (0.27‐1.54)	0.316	1.01 (0.34‐3.04)	0.985	2.52 (1.43‐4.44)	0.009*	0.86 (0.25‐3.01)	0.819	0.61 (0.19‐1.95)	0.403
CG+CC (n = 298)
CYP2C19 rs3758580
CT+TT (n = 335)	0.54 (0.20‐1.51)	0.236	1.23 (0.51‐2.97)	0.638	1.86 (0.55‐6.24)	0.308	1.11 (0.67‐1.84)	0.686	3.74 (0.79‐17.77)	0.075	1.29 (0.41‐4.12)	0.663
CC (n = 308)
CYP2C19 rs4244285
GG (n = 310)	1.82 (0.65‐5.07)	0.244	0.80 (0.33‐1.93)	0.623	0.67 (0.22‐2.06)	0.481	0.89 (0.54‐1.48)	0.657	0.27 (0.06‐1.26)	0.073	0.77 (0.24‐2.44)	0.651
AG+AA (n = 334)
CYP2C19 rs4986894
TT (n = 310)	1.82 (0.65‐5.07)	0.244	0.80 (0.33‐1.93)	0.623	0.67 (0.22‐2.06)	0.481	0.89 (0.54‐1.48)	0.657	0.27 (0.06‐1.26)	0.073	0.77 (0.24‐2.44)	0.651
CT+CC (n = 334)
NUDT15 rs116855232
CT+TT (n = 124)	1.41 (0.45‐4.45)	0.568	4.97 (2.06‐11.97)	0.003*	0.75 (0.17‐3.47)	0.713	0.89 (0.46‐1.71)	0.73	1.82 (0.46‐7.13)	0.290	1.41 (0.38‐5.28)	0.709
CC (n = 520)

P value has been adjusted for age, gender and BMI.

Considering the low frequencies of some minor genotypes, seven SNPs were stratified based on the dominant or recessive model.

Notably, the rs116855232 TT genotype‐related risk is markedly higher (OR = 7.82, 95% CI = 2.05–29.87, adjusted P = 0.018) in leukopenia.

*Significant associations denoted in bold were performed with Bonferroni corrections.